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occluded for 30-60 seconds. The measurement is the difference between these two read-
ings.
Results: Temperature measurements were made in 15 lesions from 11 patients with a
mean age of 62 years, 90% male, 36% diabetes and 82% with acute coronary syn-
dromes. Measurement were made in all three major coronary arteries. The mean tem-
perature elevation was 0.4 (range 0-2.2oC). Five of the 15 lesions had a mean
temperature elevation of 0.9 oC (range 0.3-2.2) over baseline while the rest of lesions
(n=10) had no temperature change from baseline. No complications were observed with
its clinical application. Conclusion: A thermal sensing catheter that temporarely occludes
flow during the measurement is a safe and feasible means to accurately measure lesion
temperature. The system used in this trial holds promise as a new diagnostic tool to
guide treatment of coronary lesions.
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PCI of chronic total occlusion is technically challenging. The direct visualization of the
occlusion could help to steer the guidewire and increase the safety and success rate of
recanalization procedures. Intravascular Optical Coherence Tomography (OCT) is a new
light emitting technique, which provides high resolution cross-sectional images of the
vessel wall (~ 15 microns). We hypothesised that OCT is suitable to give forward-looking
information on vessel anatomy.
An OCT catheter (Lightlab Inc) was modified to emit near infrared (1340nm) light in an
angle of 30° from the axis of the catheter. The catheter is rotating around his axis provid-
ing a cone like beam providing images of structures that are located in front of the cathe-
ter.
Forward looking OCT was performed in a cryogel (PVA 5%) phantom, which mimics the
anatomy of an artery with a total occlusion by introducing the modified catheter into the
phantom and advancing the catheter. After image acquisition the phantom was cut open
and the morphology was assessed (figure 1).
It was feasible with OCT to detect the total occlusion, the geometry and the size of the
phantom. The surface of the occlusion was clearly delineated. Details of the vessel mim-
icking phantom wall were clearly visible. Comparison with the structure of the phantom
showed remarkable agreement between images and details of the vessel wall and the
occlusion.
Forward looking OCT is feasible in-vitro and may provide valuable in-vivo information for
recanalization of chronic total occlusions.
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1024-47 Sirolimus Versus Plain Old Balloon Angioplasty Small 
Vessels
David R. Holmes, Jr., Jeffrey Moses, Martin Leon, Mark Midei, Michael Mooney, Donald 
Baim, Samuel DeMaio, Jeffrey Popma, Richard Kuntz, The SIRIUS Trial Investigators, 
Mayo Clinic, Rochester, MN
Background: Results of stenting in smaller vessels compared with angioplasty alone
have been variable and conflicting particularly in regards to restenosis prevention and fol-
low up events. The Sirolimus-eluting stent may improve the outcome in these vessels.
Purpose: In vessels < 3mm to evaluate effectiveness of the Sirolimus-eluting Bx velocity
stent in the randomized SIRIUS Trial and compare it to patients treated in BENESTENT I
+ II and STRESS with conventional PTCA.
Population: 370 lesions treated with Sirolimus-eluting stent in the SIRIUS Trial and 437
lesions treated with PTCA alone in BENESTENT I (n=120), BENESTENT II (n=209) and
STRESS (n=108). All patients had treatment of de novo lesions in vessels with RVD <
3.0mm
Results: Sirolimus stent patients were at higher risk;
1) The mean reference RVD was 2.56±0.28 in Sirolimus versus 2.65±0.24mm in the
PTCA group
2) Lesion length in Sirolimus was significantly longer 14.0±5.8 versus 7.9±2.6mm
3) Diabetes was more frequent 27% in Sirolimus versus 12.1% in PTCA Group
Despite these higher risk characteristics, patients treated with Sirolimus had improved
outcome at 270 days (table)
>Conclusions: Implantation of Sirolimus-eluting stents in small vessels < 3.0mm results
in markedly improved outcome compared with conventional PTCA alone.
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the Drug-Eluting Stent Era
Alaide Chieffo, Erminio Bonizzoni, Dejan Orlic, Renata Rogacka, Flavio Airoldi, Matteo 
Montorfano, Nicola Corvaja, Ghada W Michail, Antonio Colombo, San Raffaele Hospital, 
Milan, Italy, EMO Centro Cuore Columbus, Milan, Italy
Background Intraprocedural stent thrombosis (IPST) is an unheard event outside spe-
cific settings such as acute myocardial infarction, thrombus containing lesions or dissec-
tions. Some concerns have been raised due to the implantation of long stent required by
sirolimus-eluting stents (SES). The aim of our study was to investigate the frequency and
the predictors of IPST in drug-eluting stent era. 
Methods and Results Between April 2002 and August 2003, 683 patients (pts) were
treated with Cypher (Cordis, Johnson and Johnson Company, Warren, NJ) Sirolimus-
Eluting Stent (SES) implantation in San Raffaele Hospital and EMO Centro Cuore
Columbus. 146 (21%) patients were diabetics,161 (23%) had unstable angina. 239pts
(35%) were pretreated with glycoprotein IIb/IIIa inhibitors (IIb/IIIa). Maximum stent length
per vessel (per patient) was 43.2±28.4mm. IPST occurred in 5 (0.7%) patients. None of
the patients with IPST was pretreated with IIb/IIIa Multivariate analysis using exact test
for logistic regression modelling showed that maximum stent length per vessel (exact
odds ratio [OR]=1.039 , 95% confidence interval [CI]= 1.016-1.067; p=0.001) and the
lack of use of elective IIb/IIIa (OR=11.6,CI=1.5 -∝,p=0.016) were independent correlates
of IPST.
Conclusions Stent length and no pretreatment with IIb/IIIa are independently correlated
with occurrence of IPST. Particular attention will need to be paid to this new emerging
complication when long stents are being used. 
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Sunao Nakamura, Tamil S. Selvan, Jang-Ho Bae, Yeo H. Cahyadi, Orathai Pachirat, New 
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Background: Although previous clinical studies utilizing sirolimus-eluting stents (SES) in
simple coronary lesions demonstrated an impressive reduction in intimal hyperplasia and
restenosis, long –term efficacy of SES in treating patients with chronic total occlusion is
still unknown. A prospective Asian multicenter registry was set up in 5 high volume Asian
centers to evaluate the efficacy of SES in the treatment of chronic total occlusions.
Method: A total of 88 patients with 102 chronic total occlusions (male 70.5% mean age
69.2) (defined as TIMI flow grade 0 and the age of occlusion was more than 3 months:
LAD=42.1% LCX=27.3% RCA=30.6%) were treated with SES after successful lesion
crossing and dilating the lesions. We evaluate immediate and long-term clinical results by
6 months and 12 months angiography. Results: See table for clinical results. The 12
months QCA results will be available at the time of presentation. Conclusion: These
results showed utilizing the SES can dramatic suppress the restenosis rate with chronic
total occlusive lesions.
Safety Measures
(Events up to 270 
days)
Sirolimus-Eluting 
Bx VELOCITY(TM)
(n=370 patients
n=370 lesions)
Historical Control 
Balloon
(n=429 patients
n=437 lesions)
Difference
(95% CI)
MACE (Any Death, 
MI, TLR)
8.4% (31/370) 24.7% (106/429) -16.3%{-21.3%,-11.4%}
Death 1.1% (4/370) 0.0% (0/429) 1.1% {0.0%, 2.1%}
Any MI 3.0% (11/370) 3.3% (14/429) -0.3% {-2.7%, 2.1%}
Target Lesion 
Revasc
5.1% (19/370) 24.0% (105/437) -18.9% {-23.5%, -
14.3%}
(Sub)acute 
Occlusion
0.3% (1/370) 1.4% (6/429) -1.1% {-2.4%, 01.%)
Number of patients 88
Procedural success (%) 100
MACE at 30 days (%) 0
Reference diameter (mm) 2.86±0.66
MLD post (mm) 2.65±0.55
MLD at 6 months (mm) 2.54±0.44
Restenosis rate (%) 3.4
TVR (%) 4.5
MACE at 6 months (%) 4.5
